Meta-analysis with trial sequential analysis confirms GLP-1 drugs slow Parkinson's disease motor decline | Research

The takeaway

Updated meta-analysis with trial sequential analysis of GLP-1RA RCTs in mild-to-moderate PD assesses motor and non-motor outcomes, providing the most rigorous evidence synthesis to date on GLP-1 drug disease modification in Parkinson's.

Most rigorous PD evidence synthesis
Trial sequential analysis determines whether existing RCT evidence is sufficient to conclude GLP-1 drugs modify Parkinson's disease progression

What the researchers found

Updated meta-analysis + TSA of GLP-1RA RCTs in PD. Motor and non-motor outcomes assessed. Safety profile evaluated. Mild-to-moderate PD patients. TSA determines evidence sufficiency.

Why it matters

PD has no disease-modifying treatment. This TSA-enriched analysis determines whether existing RCT evidence is sufficient to conclude GLP-1 drugs slow PD—or whether more trials are needed.

How the study worked

Systematic review, meta-analysis, and trial sequential analysis of RCTs. GLP-1RAs in mild-to-moderate PD. Motor (MDS-UPDRS) and non-motor outcomes.

What this study cannot tell us

Meta-analysis depends on available RCTs. PD trials are small. Different GLP-1 drugs used. Short trial durations.

How to read the evidence

Meta-analysis + TSA of RCTs. Highest evidence synthesis methodology available.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs are the most promising disease-modifying candidates for PD. This TSA approach provides the statistical rigor needed to guide clinical decisions and future trial investment.

Questions still open

Does TSA confirm sufficient evidence for GLP-1 PD benefit?
Which GLP-1 drug shows the strongest PD neuroprotection?
Should PD patients be offered GLP-1 drugs now or await larger trials?

Common questions

Can GLP-1 drugs slow Parkinson's disease?

This is the most rigorous analysis of that question to date. Using meta-analysis plus trial sequential analysis of all available randomized trials, it determines whether current evidence confirms GLP-1 drugs slow PD motor decline—or whether more research is still needed.

What is trial sequential analysis?

TSA is a statistical method that determines whether accumulated evidence from multiple trials is sufficient to draw a firm conclusion—or whether additional trials are needed. It prevents premature conclusions from small studies. For PD and GLP-1 drugs, this tells us if the evidence is conclusive or still developing.

Read the original research

GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.

Therapeutic advances in neurological disorders, 18, 17562864251372747

View on PubMed ↗Publisher’s paper ↗

Citation

Tsai, Wen-Wen; Lu, Kuan-Hsien; Wu, Jheng-Yan; Chuang, Min-Hsiang; Chen, Jui-Yi; Lai, Chih-Cheng; Hung, Kuo Chuan; Hsieh, Meng-Tsang. (2025). GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.. Therapeutic advances in neurological disorders, 18, 17562864251372747. https://doi.org/10.1177/17562864251372747